BCG vaccine
- Generic Name
- BCG vaccine
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 8VJE55B0VG
- Background
BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
- Associated Conditions
- Non-Invasive Bladder Urothelial Carcinoma, Recurrent Superficial Bladder Cancer, Tuberculosis (TB), Urothelial Carcinoma Recurrent, Carcinoma in situ of urinary bladder
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- Conditions
- Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder NeoplasmsCarcinoma in Situ
- Interventions
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 308
- Registration Number
- NCT06833073
- Locations
- 🇺🇸
University of Missouri Health Care ( Site 0126), Columbia, Missouri, United States
🇺🇸NHO Revive Research Institute, LLC ( Site 0137), Lincoln, Nebraska, United States
🇺🇸OHSU Knight Cancer Institute - South Waterfront ( Site 0110), Portland, Oregon, United States
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- Drug: N-803 and Gemcitabine
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06829823
BCG for Therapeutic Use Phase Ⅲ Clinical Trial
- Conditions
- BCG
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Target Recruit Count
- 438
- Registration Number
- NCT06747455
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of USTC, Hefei, Anhui, China
🇨🇳Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
- Conditions
- Non-Muscle Invasive Bladder CarcinomaStage 0is Bladder Cancer AJCC v8Stage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8
- Interventions
- Procedure: CystoscopyOther: Home Health EncounterOther: Questionnaire Administration
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT06704191
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
ID93/GLA-SE Vaccination + BCG Challenge
- Conditions
- Tuberculosis
- Interventions
- Biological: ID93/GLA-SE
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 48
- Registration Number
- NCT06670755
- Locations
- 🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxfordshire, United Kingdom
Trained Immunity in Fungal Infection and Its Mechanism
- Conditions
- BCG Vaccination
- Interventions
- First Posted Date
- 2024-10-07
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Zhongnan Hospital
- Target Recruit Count
- 79
- Registration Number
- NCT06628544
- Locations
- 🇨🇳
Wuhan University, Wuhan, Hubei, China, China
Clinical Study to Investigate the Safety and Tolerance of Therapeutic BCG in Postoperative Adjuvant Therapy in Subjects With Moderate to High-risk Non-muscular Invasive Bladder Cancer (NMIBC)
- Conditions
- Non-muscular Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Chengdu CoenBiotech Co., Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT06350838
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC
- Conditions
- Bladder Cancer
- Interventions
- Procedure: Transurethral resection of bladder tumorProcedure: Transurethral cryoablation
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 190
- Registration Number
- NCT06324058
Live Vaccines and Innate Immune Training in COPD.
- Conditions
- COPDTrained Innate Immunity
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Josefin Eklöf
- Target Recruit Count
- 60
- Registration Number
- NCT06257212
- Locations
- 🇩🇰
Department of Internal Medicine, Section of Respiratory Medicine, Hellerup, Copenhagen, Denmark
Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
- Conditions
- Non-Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Chengdu CoenBiotech Co., Ltd
- Target Recruit Count
- 412
- Registration Number
- NCT06241755
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.